Ascletis Announces U.S. IND Filing of Oral Antiviral ASC10 for Monkeypox Indication
- Wednesday, October 26, 2022, 7:11
- Business
- Add a comment
–ASC10 has two indications: monkeypox and SARS-CoV-2 virus infections. The Investigational New Drug (IND) application of the latter was approved by the U.S. Food and Drug Administration (FDA) in August 2022 and Phase Ib clinical trial in COVID-19 patients is underway in the U.S….
About the Author
adminasapcorp has written 41555 stories on this site.